Bladder Cancer - Results from #120

Molecular changes during progression from non-muscle invasive to advanced urothelial carcinoma. October 16, 2019

Utility and Validation of the AUA/SUO Risk Grouping for Non-muscle Invasive Bladder Cancer in a Contemporary Cohort. October 16, 2019

Intravesical Treatment with Electro-Mediated Administration of Mytomicin C as Prophylaxis for Intermediate and High-Risk Nonmuscle-Invasive Bladder Cancer: A Retrospective Multicenter Study. October 16, 2019

FOXA1 and Oncogenic HRAS are Required for Maintenance of Urothelial Hyperplasia - Expert Commentary October 15, 2019

Application of nomograms in the prediction of overall survival and cancer-specific survival in patients with T1 high-grade bladder cancer. October 15, 2019

Update on the Guideline of Guidelines: Non-Muscle Invasive Bladder Cancer. October 15, 2019

Neoadjuvant Chemotherapy Is Not Associated with Adverse Perioperative Outcomes after Robot-Assisted Radical Cystectomy: A Case for Increased Utilization from the IRCC. October 15, 2019

SUNA 2019: Utilizing Change Management for Successful Implementation of Blue Light Cystoscopy October 14, 2019

Targeting immunotherapy for bladder cancer by using anti-CD3 × CD155 bispecific antibody. October 14, 2019

What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Mus October 14, 2019

Pathologic measures of quality compare favorably in patients undergoing robot-assisted radical cystectomy to open cystectomy cohorts: a National Cancer Database analysis. October 14, 2019

Intratumoral IL22-producing cells define immunoevasive subtype muscle-invasive bladder cancer with poor prognosis and superior nivolumab responses. October 14, 2019

Systematic screening of protein-coding gene expression identified HMMR as a potential independent indicator of unfavorable survival in patients with papillary muscle-invasive bladder cancer. October 11, 2019

Different models for prediction of radical cystectomy postoperative complications and care pathways. October 11, 2019

Graham Roberts Study protocol: first 'trials within cohort study' for bladder cancer. October 11, 2019

A single-institute experience of trimodal bladder-preserving therapy for histologic variants of urothelial carcinoma. October 10, 2019

Clinically node-positive (cN+) urothelial carcinoma of the bladder treated with chemotherapy and radical cystectomy: Clinical outcomes and development of a postoperative risk stratification model. October 10, 2019

Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive? October 10, 2019

PLEKHS1: A new molecular marker predicting risk of progression of non-muscle-invasive bladder cancer. October 10, 2019

The Prognostic Value of Tumor Regression Grades Combined With TNM Classification in Patients With Muscle-Invasive Bladder Cancer Who Underwent Neoadjuvant Chemotherapy Followed by Radical Cystectomy. October 9, 2019

Page 7 of 319